Cover Image

Efficacy of intralesional meglumine antimoniate in the treatment of canine tegumentary leishmaniasis: A Randomized controlled trial.

Show other versions (1)

Dogs living in areas of Leishmania (Viannia) braziliensis transmission may present canine tegumentary leishmaniasis (CTL) characterized by cutaneous or muzzle ulcers as well as asymptomatic L. braziliensis infection. It is not clear if dogs participate in the transmission chain of L. braziliensis to...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jamile Lago (Author), Deborah Fraga (Author), Luiz Henrique Guimarães (Author), Tainã Lago (Author), Yuri de Jesus Silva (Author), Ednaldo Lago (Author), Guilherme L Werneck (Author), Olívia Bacellar (Author), Edgar M Carvalho (Author)
Format:	Book
Published:	Public Library of Science (PLoS), 2023-02-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy of intralesional meglumine antimoniate in the treatment of canine tegumentary leishmaniasis: A Randomized controlled trial
by: Jamile Lago, et al.
Published: (2023)

Correction: Efficacy of intralesional meglumine antimoniate in the treatment of canine tegumentary leishmaniasis: A Randomized controlled trial.
by: Jamile Lago, et al.
Published: (2023)

Clinical and histopathologic features of canine tegumentary leishmaniasis and the molecular characterization of Leishmania braziliensis in dogs.
by: Jamile Lago, et al.
Published: (2019)

Comparison of Intralesional Sodium Stibogluconate versus Intralesional Meglumine Antimoniate for the Treatment of Leishmania major Cutaneous Leishmaniasis
by: Michal Solomon, et al.
Published: (2024)

Pharmacometabolomics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis
by: Deninson Alejandro Vargas, et al.
Published: (2019)

Intralesional infiltration versus parenteral use of meglumine antimoniate for treatment of cutaneous leishmaniasis: A cost-effectiveness analysis.
by: Nayara C Brito, et al.
Published: (2019)

Comparison of Oral Zinc Sulfate with Systemic Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis
by: Mohamad Javad Yazdanpanah, et al.
Published: (2011)

An old drug and different ways to treat cutaneous leishmaniasis: Intralesional and intramuscular meglumine antimoniate in a reference center, Rio de Janeiro, Brazil.
by: Carla Oliveira-Ribeiro, et al.
Published: (2021)

Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis.
by: Brandon A Berger, et al.
Published: (2017)

Clinical and Parasitological Features of Patients with American Cutaneous Leishmaniasis that Did Not Respond to Treatment with Meglumine Antimoniate.
by: Jairo E Perez-Franco, et al.
Published: (2016)

Associated-risk determinants for anthroponotic cutaneous leishmaniasis treated with meglumine antimoniate: A cohort study in Iran.
by: Mohammad Reza Aflatoonian, et al.
Published: (2019)

Natural resistance to meglumine antimoniate is associated with treatment failure in cutaneous leishmaniasis caused by Leishmania (Viannia) panamensis.
by: Olga Lucía Fernández, et al.
Published: (2024)

Development and Characterization of a Semi-Solid Dosage Form of Meglumine Antimoniate for Topical Treatment of Cutaneous Leishmaniasis
by: Diana Berenguer, et al.
Published: (2019)

Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study.
by: Maria Del Mar Castro, et al.
Published: (2017)

American tegumentary leishmaniasis: severe side effects of pentavalent antimonial in a patient with chronic renal failure
by: Sílvio Alencar Marques, et al.
Published: (2019)

Dynamics of American tegumentary leishmaniasis in a highly endemic region for Leishmania (Viannia) braziliensis infection in northeast Brazil.
by: Juliana Silva, et al.
Published: (2017)

PCR in the investigation of canine American tegumentary leishmaniasis in northwestern Paraná State, Brazil
by: Velasquez Leonardo Garcia, et al.
Published: (2006)

Vaccines for leishmaniasis and the implications of their development for American tegumentary leishmaniasis
by: Beatriz Coutinho De Oliveira, et al.
Published: (2020)

First Report on Infant Acute Urticaria after Mother's Parenteral Use of Meglumine Antimoniate (Glucantime): A Case Report
by: Omid MOZAFARI, et al.
Published: (2016)

Periungual tegumentary leishmaniasis: a diagnostic challenge
by: Bruna Morassi Sasso, et al.
Published: (2017)

Complementary exams in the diagnosis of american tegumentary leishmaniasis
by: Ciro Martins Gomes, et al.
Published: (2014)

Tegumentary leishmaniasis and coinfections other than HIV.
by: Dalila Y Martínez, et al.
Published: (2018)

Evaluation of Correlation between the in Vitro Susceptibility of Field Isolates of Leishmania major and Clinical Outcomes of Meglumine Antimoniate Therapy in Fars Province, Iran
by: Nafiseh Ghobakhloo, et al.
Published: (2017)

Efficacy of intra-lesional injections of meglumine antimoniate once a week vs. twice a week in the treatment of cutaneous leishmaniasis caused by L. tropica in Iran: A randomized controlled clinical trial.
by: Amir Javadi, et al.
Published: (2022)

"Cheaper and better": Societal cost savings and budget impact of changing from systemic to intralesional pentavalent antimonials as the first-line treatment for cutaneous leishmaniasis in Bolivia.
by: Daniel Eid Rodríguez, et al.
Published: (2019)

American tegumentary leishmaniasis - a case of therapeutic challenge
by: Daíne Vargas Couto, et al.
Published: (2014)

Clinical and immunological characteristics of tegumentary leishmaniasis cases in Bolivia.
by: Cristina Ballart, et al.
Published: (2021)

Epidemiological surveillance of tegumentary leishmaniasis: local territorial analysis
by: Valdenir Bandeira Soares, et al.

Use of the polymerase chain reaction for the diagnosis of American tegumentary leishmaniasis
by: Thales Augusto Barçante, et al.

Geospatial-temporal distribution of Tegumentary Leishmaniasis in Colombia (2007-2016).
by: Giovanny Herrera, et al.
Published: (2018)

Cost-effectiveness of prevention strategies for American tegumentary leishmaniasis in Argentina
by: Pablo Wenceslao Orellano, et al.
Published: (2013)

Antimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B.
by: Gloria Morizot, et al.
Published: (2016)

Atypical Manifestations of Cutaneous Leishmaniasis in a Region Endemic for Leishmania braziliensis: Clinical, Immunological and Parasitological Aspects.
by: Luiz Henrique Guimarães, et al.
Published: (2016)

American tegumentary leishmaniasis: correlations among immunological, histopathological and clinical parameters
by: Ana Luiza Grizzo Peres Martins, et al.
Published: (2014)

Prediction score for antimony treatment failure in patients with ulcerative leishmaniasis lesions.
by: Cristian Valencia, et al.
Published: (2012)

IFN-γ production to leishmania antigen supplements the leishmania skin test in identifying exposure to L. braziliensis infection.
by: Daniel Schnorr, et al.
Published: (2012)

Temporal patterns, spatial risks, and characteristics of tegumentary leishmaniasis in Brazil in the first twenty years of the 21st Century.
by: Vinícius Silva Belo, et al.
Published: (2023)

Risk factors for antimony treatment failure in American Cutaneous Leishmaniasis in Northwestern-Argentina.
by: María F García-Bustos, et al.
Published: (2021)

Acute erythroid toxicity in visceral leishmaniasis: A rare complication of antimonial therapy
by: Sharma Sunita, et al.
Published: (2008)

Localized skin inflammation during cutaneous leishmaniasis drives a chronic, systemic IFN-γ signature.
by: Camila Farias Amorim, et al.
Published: (2021)